Keywords: abraxis, biosci, gets, chinese, marketing, approval, abraxane
Abraxis BioSci gets Chinese marketing approval for Abraxane
Article | 21 July 2008
Abraxis BioScience has received approval from the China State Food and Drug Administration to market Abraxane (albumin-bound paclitaxel for injection) ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Is failure to adopt business process management putting the pharma industry at risk?
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
